Clinical trial registry data indicates that researchers plan to start a clinical trial for an additional dose of a COVID-19 vaccine candidate co-developed by China's CanSino Biologics Inc and a military-backed research unit, Reuters news agency reported on Friday.
This new two-dose Phase 1 trial will test the safety of two doses and their ability to generate an immune response, showed a registration record published on 17 September 2020.
A single dose of the vaccine candidate Ad5-nCoV, one among a handful that China is pursuing, has final-stage trials lined up in Pakistan and Russia. The candidate has been approved for use in the Chinese military.
Reportedly, scientists outside the company have expressed concern that the effectiveness of Ad5-nCoV, which uses a common cold virus many people have contracted to carry genetic traces of COVID-19, could be limited.
In response, CanSino had said there was no evidence that existing immunity against the common cold virus could severely hurt Ad5-nCoV's ability to trigger antibodies against COVID-19, citing data gathered from a single dose-based Phase 2 trial.
Subsequently, in July 2020, researchers working on Ad5-nCoV said a flexible additional dose might be able to provide enhanced immune response, based on their previous experience using this method to develop a common cold virus-based Ebola vaccine.
Researchers now expect to recruit 168 healthy adults to take two doses of Ad5-nCoV for the trial estimated to begin on 20 September 2020 in China's Wuhan.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer